Login
Beam Therapeutics Inc. logo

Beam Therapeutics Inc.

beamtx.com

What Do They Do?

Develops gene-editing treatments for patients with sickle cell disease and other genetic diseases, using base editing and delivery technologies.

How Do They Make Money?

Beam earns money from license agreements: customers pay upfront fees when received or due, and Beam earns the revenue as it fulfills the agreement's obligations.

FY2025 revenue

Who Are Their Customers?

Beam seeks partnerships with other companies through its technology platform and has license agreements with customers.

Do Revenues Turn Into Profits?

No. It lost $80M in FY2025.

Operating income, FY2025
−275% of revenue
▲ +8% (Loss) vs FY2024 (−$415.6M, −654%)
Net income, FY2025
−57% of revenue
▲ +79% (Loss) vs FY2024 (−$376.7M, −593%)
Free cash flow, FY2025
−258% of revenue
▼ −1% (Loss) vs FY2024 (−$356.2M, −561%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −97%
vs $9.7M in Q3 FY2025
Net income
▼ −19% (Loss)
vs −$112.6M in Q3 FY2025
  • Mar 5, 2026 Beam and Bio Palette ended their license agreement A standby license from Kobe gave Beam an exclusive license to patents of the same scope as its prior Bio Palette license.

Growing. Revenue grew 2.7x in 4 years, from $51.8M in FY2021 to $139.7M in FY2025, about 28% a year.

Stated disease priorities The older report described programs across hematology, immunology/oncology, and genetic diseases; the latest report frames its lead-program priorities around hematology and genetic diseases.

Who Do They Compete With?

Competes with Life Edit, Metagenomi, Revvity, Aurora Therapeutics, Mammoth Biosciences, YolTech Therapeutics, HuidaGene Therapeutics, Intellia Therapeutics, CRISPR Therapeutics, Vertex Pharmaceuticals, Genetix Biotherapeutics, Novartis Pharmaceuticals, Kamau Therapeutics, Fulcrum Therapeutics, Tessera Therapeutics, Cimeio Therapeutics, Agios Pharmaceuticals, Wave Life Sciences, Prime Medicine, and Moderna

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support